Can a new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin degludec

Drugs

Volumn 72, Issue 18, 2012, Pages 2319-2325

  Robinson, Jennifer D ^a   Neumiller, Joshua J ^b   Keith Campbell, R ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Diabetes mellitus; insulin degludec

Indexed keywords

GLUCOSE; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN GLARGINE; MEGLITINIDE; METFORMIN; SULFONYLUREA;

BODY MASS; CLINICAL PRACTICE; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; STEADY STATE; WEIGHT GAIN;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; PATIENT CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84871242664     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11642240-000000000-00000     Document Type: Review

References (11)

1. Keen H, Glynne A, Pickup JC, et al. Human insulin produced by recombinant DNA technology; safety and hypoglycaemic potency in healthy men. Lancet 1980;2: 398-401
2. Jonassen I, Haelund S, Hoeg-Jensen, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012;29(8):2104-14.
3. Kurtzhals P, Heise T, Strauss HM, et al. Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec. American Diabetes Association 71st Scientific Sessions; 2011 Jun 24-28; San Diego (CA
4. Nosek L, Heise T, Bottcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose lowering effect (poster). American Diabetes Association 71st Scientific Sessions; 2011 Jun 24-28; San Diego (CA)
5. Heise T, Hovelmann U, Nosek L, et al. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine (poster). American Diabetes Association 71st Scientific Sessions; 2011 Jun 24-28; San Diego (CA)
6. Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes; a 16-week, randomized, open-label, phase 2 trial. Lancet 2011; 377; 924-31
7. Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2); a phase 3, randomized, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379; 1498-507
8. Birkeland KI, Home PD, Wendisch U, et al. Insulin degludec in type 1 diabetes. Diabetes Care 2011; 34; 661-5
9. Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1); a phase 3, randomized, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379; 1489-97
10. Meneghini L, Atkin SL, Bain S, et al. Flexible once-daily dosing of insulin degludec does not compromise glycemic control or safety compared to insulin glargine given once daily at the same time each day in people with type 2 diabetes (abstract no. 35-LB; online). Available from URL; http://professional.diabetes.org/Abstracts-Display.aspx?TYP=1&CID=88737 (Accessed 2012 Nov 1
11. Heise T, Tack CJ, Cuddihy R, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naïve people with type 2 diabetes. Diabetes Care 2011; 34; 669-74